Yehonatan Medical News
3 articles
growth-positive
Revolutionary multi-patient ventilators for Covid ICU care
Israeli startup Yehonatan Medical has developed a groundbreaking ventilation system that can be used by multiple patients simultaneously. The system, developed in collaboration with Dr. Ori Efrati of Sheba Medical Center, addresses the shortage of ventilators and staff trained to monitor them in Covid-19 intensive care units. The system is based on the BiPAP non-invasive ventilation machine and has a built-in disinfecting mechanism. It allows for remote monitoring of patients and is currently in advanced trials at Sheba Medical Center. Yehonatan Medical is the medical arm of Mofet Etzion, an Israeli defense industry company.
CustomersPartners
growth-positive
Israeli ventilation system could give COVID-19 the 'smart' treatment
Israeli startup Yehonatan Medical has developed a state-of-the-art ventilation system that can treat between three and five patients simultaneously, addressing the shortage of ventilators and overwhelming of staff in COVID-19 wards. The system is based on the BipaP non-invasive ventilation machine and includes additional features powered by artificial intelligence. The innovation has been hailed as a game-changer by Professor Ori Efrati, director of the Pediatric Pulmonary Unit at Sheba Medical Center. Yehonatan Medical is the medical department of Mofet Etzion, a company that specializes in security and military innovations for the Israel Defense Forces.
Customers
growth-positive
Revolutionary Israeli Ventilation System Provides Smart Solutions for COVID ICU Wards - Hamodia.com
Yehonatan Medical, in collaboration with Sheba Medical Center, has developed a state-of-the-art ventilation system that can treat multiple patients simultaneously. The system resolves issues faced by corona ICU wards, such as the shortage of ventilators and the lack of highly trained ICU staff. It is a groundbreaking innovation that delivers personalized care in a multi-user format and includes features based on AI technology. The system is currently in advanced phase trials and is expected to be ready for mass marketing in the coming months.
CustomersPartners
